Single Patient Protocol: A Phase II Study Using the Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated Neoantigens in a Patient With Metastatic Cancer Plus the Administration of Pembrolizumab

NCT04135092 · clinicaltrials.gov ↗

NO_LONGER_AVAILABLE

Status

NIH

Sponsor class

Interventions

BIOLOGICAL: Individual Patient TCR Transduced PBL
DRUG: Cyclophosphamide
DRUG: Fludarabine
DRUG: Aldesleukin
DRUG: Pembrolizumab

Sponsor

National Institutes of Health Clinical Center (CC)